News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Vaxcyte’s (Nasdaq: PCVX) $500 Million Follow-On OfferingApril 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to MedStream Anesthesia on Its Sale to National Partners in HealthcareApril 2023
News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Regulus Therapeutics’ (Nasdaq: RGLS) $15.0 Million Private PlacementApril 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor for Harpoon Therapeutics’ (Nasdaq: HARP) $25 Million Private PlacementMarch 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor for Wellvana’s $84 Million Capital RaiseMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for 89bio’s (Nasdaq:ETNB) Upsized $275 Million Follow-On OfferingMarch 2023
News | NewsSVB Securities Sets Record Straight on the Current and Previous Role of Chief Administrative Officer Joseph GentileMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Stagwell’s (NASDAQ: STGW) $108 Million Follow-On OfferingMarch 2023
News | NewsSVB Securities Continues its Independent Operations Unimpeded by Silicon Valley Bank’s Receivership ProceedingsMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Clearwater Analytics’ (NYSE: CWAN) $195 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Revolution Medicines’ (Nasdaq: RVMD) $300 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for 2seventy bio’s (Nasdaq: TSVT) Upsized $125 Million Follow-On OfferingMarch 2023
